ClinicalTrials.gg
CompletedNCT02738775Updated Jul 15, 2021Results posted

Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

A Phase 2 interventional study of Ublituximab and Placebo in Multiple Sclerosis, sponsored by TG Therapeutics, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-07-15.

Sponsored by TG Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing ublituximab in Multiple Sclerosis — 5 open to participants now, 7 under way, 4 of them phase 3. ublituximab · Multiple Sclerosis.

Enrollment
9th of 10
49 · median 355
Started
2016
the only one that year
Phase 2
2 of 10
1 open now
Registered
1st of 10
by date
Lead sponsor
8 of 10
TG Therapeutics, Inc.

Among the 10 studies testing ublituximab in Multiple Sclerosis, this one is the 9th largest by enrollment, is the only one that started in 2016, is one of 2 in phase 2, and was the 1st registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

5 of the 10 studies testing ublituximab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ublituximab

ublituximab: first FDA approval 2022 (BRIUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ublituximab in Multiple Sclerosis, or all of them as a file.
02

Study summary

This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in participants with relapsing forms of multiple sclerosis.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • multiple sclerosis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of relapsing multiple sclerosis
  • Active disease
  • Greater than or equal to (≥) 2 relapses in prior 2 years or 1 relapse in the year prior to screening and/or ≥1 gadolinium (Gd) enhancing lesion

Exclusion criteria

Exclusion Criteria:

  • Treatment with anti-cluster of differentiation 20 (CD20) monoclonal antibody within the last 12 months
  • Treatment with alemtuzumab within the last 12 months
  • Pregnant or nursing mothers
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participant received intravenous (IV) infusion of ublituximab 150 milligrams (mg)/4 hour (hr) on Day 1, 450 mg/3 hr on Day 15 and 450 mg/1.5 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /3 hr on Day 15 before receiving ublituximab.

    Biological: Ublituximab · Drug: Placebo

  • Experimental
    Cohort 2

    Participant received IV infusion of ublituximab 150 mg/4 hr on Day 1, 450 mg/1.5 hr on Day 15 and 450 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /1.5 hr on Day 15 before receiving ublituximab.

    Biological: Ublituximab · Drug: Placebo

  • Experimental
    Cohort 3

    Participant received IV infusion of ublituximab 150 mg/4 hr on Day 1, 450 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.

    Biological: Ublituximab · Drug: Placebo

  • Experimental
    Cohort 4

    Participant received IV infusion of ublituximab 150 mg/3 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /3 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.

    Biological: Ublituximab · Drug: Placebo

  • Experimental
    Cohort 5

    Participant received IV infusion of ublituximab 150 mg/2 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /2 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.

    Biological: Ublituximab · Drug: Placebo

  • Experimental
    Cohort 6

    Participant received IV infusion of ublituximab 150 mg/1 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /1 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.

    Biological: Ublituximab · Drug: Placebo

Interventions

  • BiologicalUblituximab

    Administered as an IV infusion.

    Also known as: TG-1101

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Responder Rate of B-Cell Depletion at Week 4

    Responders Rate is defined as percentage of participants with greater than or equal to (≥) 95% reduction of B cells (cluster of differentiation 19 positive \[CD19+\] cells) within 2 weeks after the second infusion (Day 15).

    Time frame: Week 4

Secondary outcomes

  1. Number of New Gadolinium (Gd)-Enhancing T1 Lesions at Weeks 24 and 48

    The Gd-enhancing T1 lesions were evaluated using magnetic resonance imaging (MRI) technique.

    Time frame: Weeks 24 and 48

  2. Number of New or Enlarging T2 Lesions at Weeks 24 and 48

    The new or enlarging T2 lesions were evaluated using MRI technique.

    Time frame: Weeks 24 and 48

  3. Annualized Relapse Rate (ARR)

    ARR at Week 48 is calculated as the ratio of the sum of all participants confirmed relapse counts divided by the sum of all participants treatment duration (in years).

    Time frame: Week 48

  4. Relapse Rate Reduction (RRR)

    RRR was calculated as the percentage reduction from baseline ARR to ARR at Week 48.

    Time frame: Baseline to Week 48

  5. Percentage of Relapse Free Participants

    Participant was considered as free of clinical relapse if participant had no confirmed clinical relapse before treatment discontinuation/until end of Week 48. Relapses are defined as the occurrence of new or worsening neurological symptoms attributable to multiple sclerosis (MS), and immediately preceded by a stable or improving neurological state of at least 30 days.

    Time frame: Week 48

  6. Change From Baseline in B Cells (CD19+), Memory (CD19+CD27+) and Naïve (CD19+CD27-[Negative]) B Cells

    Cluster of Differentiation (CD)19 is a marker of B cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B cell lymphomas, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). The majority of B cell malignancies express normal to high levels of CD19. Memory B cell is a type of B lymphocyte that forms part of the adaptive immune system. These cells develop within germinal centers of the secondary lymphoid organs. Their function is to memorize the characteristics of the antigen that activated their parent B cell during initial infection such that if the memory B cell later encounters the same antigen, it triggers an accelerated and robust secondary immune response. A naive B cell is a B cell that has not been exposed to an antigen. Once exposed to an antigen, the naive B cell either becomes a memory B cell or a plasma cell that secretes antibodies specific to the antigen that was originally bound.

    Time frame: Baseline, Week 1 Day 2, Week 2, Week 3 Day 15, Weeks 4, 8, 12, 16, 20, 24, Week 24 plus 2 days, Weeks 25, 28, 36, 40, 44 and 48

  7. Change From Baseline in Sustained B Cell

    Sustained B cell reduction is defined as B-cell reductions achieved on pre-dose at Week 24 and Week 48.

    Time frame: Baseline to pre-dose at Week 24 and Week 48

  8. Additional Immune Profiling-CD4+ (Cluster of Differentiation 4 Positive)

    A blood sample was collected and was sent to the laboratory for analysis of CD4+.

    Time frame: Baseline, Week 1 Day 2, Week 2, Week 3 Day 15, Weeks 4, 8, 12, 16, 20, 24, Week 24 Plus 2 Days, Weeks 25, 28, 36, 40, 44 and 48

  9. Additional Immune Profiling-CD8+ (Cluster of Differentiation 8 Positive)

    A blood sample was collected and was sent to the laboratory for analysis of CD8+.

    Time frame: Baseline, Week 1 Day 2, Week 2, Week 3 Day 15, Weeks 4, 8, 12, 16, 20, 24, Week 24 Plus 2 Days, Weeks 25, 28, 36, 40, 44 and 48

  10. Additional Immune Profiling-Interleukin 10 (IL10)

    A blood sample was collected and was sent to the laboratory for analysis of IL-10. IL-10 is an anti-inflammatory cytokine that maintains the balance of the immune response, allowing the clearance of infection while minimizing damage to the host.

    Time frame: Baseline, Weeks 2, 4, 12, 20, 24, 25, 36, 44 and 48

  11. Additional Immune Profiling-Natural Killer (NK) Cells

    A blood sample was collected and was sent to the laboratory for analysis of NK cells. Percentage of NK cells per ml of blood. NK cells are lymphocytes with the ability to kill tumor cells without deliberate immunization or activation.

    Time frame: Baseline, Week 1 Day 2, Week 2, Week 3 Day 15, Weeks 4, 8, 12, 16, 20, 24, Week 24 Plus 2 Days, Weeks 25, 28, 36, 40, 44 and 48

  12. Pharmacokinetic Parameter: Plasma Concentration of Ublituximab

    Plasma concentration is defined as the measured concentration of ublituximab.

    Time frame: Day 1 (pre-dose); Week 2; Day 15 (pre-dose); Weeks 4, 24 (pre-dose) and 25

07

Results

Posted Jul 15, 2021

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Started888988
Initially treated with placebo000100
Completed868887
Not completed020101
Withdrew: Withdrawal by subject010000
Withdrew: Adverse event000100
Withdrew: Pregnancy010000
Withdrew: Missing000001

Outcome measures

PrimaryResponder Rate of B-Cell Depletion at Week 4

Responders Rate is defined as percentage of participants with greater than or equal to (≥) 95% reduction of B cells (cluster of differentiation 19 positive \[CD19+\] cells) within 2 weeks after the second infusion (Day 15).

Time frame:
Week 4
Reported as:
Number · percentage of participants
Responder Rate of B-Cell Depletion at Week 4
percentage of participantsCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Responder Rate of B-Cell Depletion at Week 487.5 (47.35 to 99.68)100.0 (63.06 to 100)87.5 (47.35 to 99.68)100.0 (63.06 to 100)100.0 (63.06 to 100)100.0 (63.06 to 100)
SecondaryNumber of New Gadolinium (Gd)-Enhancing T1 Lesions at Weeks 24 and 48

The Gd-enhancing T1 lesions were evaluated using magnetic resonance imaging (MRI) technique.

Time frame:
Weeks 24 and 48
Reported as:
Mean · lesions
Number of New Gadolinium (Gd)-Enhancing T1 Lesions at Weeks 24 and 48
lesionsCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Week 240.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
Week 480.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.000.0 ± 0.00
SecondaryNumber of New or Enlarging T2 Lesions at Weeks 24 and 48

The new or enlarging T2 lesions were evaluated using MRI technique.

Time frame:
Weeks 24 and 48
Reported as:
Mean · lesions
Number of New or Enlarging T2 Lesions at Weeks 24 and 48
lesionsCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Week 240.38 ± 0.520.29 ± 0.490.00 ± 0.000.25 ± 0.710.00 ± 0.000.14 ± 0.38
Week 480.25 ± 0.710.00 ± 0.000.00 ± 0.000.00 ± 0.000.00 ± 0.000.00 ± 0.00
SecondaryAnnualized Relapse Rate (ARR)

ARR at Week 48 is calculated as the ratio of the sum of all participants confirmed relapse counts divided by the sum of all participants treatment duration (in years).

Time frame:
Week 48
Reported as:
Number · relapses per participant-years
Annualized Relapse Rate (ARR)
relapses per participant-yearsCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Annualized Relapse Rate (ARR)0.280.000.140.140.000.00
SecondaryRelapse Rate Reduction (RRR)

RRR was calculated as the percentage reduction from baseline ARR to ARR at Week 48.

Time frame:
Baseline to Week 48
Reported as:
Number · percentage reduction
Relapse Rate Reduction (RRR)
percentage reductionCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Relapse Rate Reduction (RRR)75.55100.0087.8089.04100.00100.00
SecondaryPercentage of Relapse Free Participants

Participant was considered as free of clinical relapse if participant had no confirmed clinical relapse before treatment discontinuation/until end of Week 48. Relapses are defined as the occurrence of new or worsening neurological symptoms attributable to multiple sclerosis (MS), and immediately preceded by a stable or improving neurological state of at least 30 days.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Relapse Free Participants
percentage of participantsCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Percentage of Relapse Free Participants75.0 (34.91 to 96.81)100.0 (63.06 to 100)87.5 (47.35 to 99.68)87.5 (47.35 to 99.68)100.0 (63.06 to 100)100.0 (63.06 to 100)
SecondaryChange From Baseline in B Cells (CD19+), Memory (CD19+CD27+) and Naïve (CD19+CD27-[Negative]) B Cells

Cluster of Differentiation (CD)19 is a marker of B cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B cell lymphomas, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). The majority of B cell malignancies express normal to high levels of CD19. Memory B cell is a type of B lymphocyte that forms part of the adaptive immune system. These cells develop within germinal centers of the secondary lymphoid organs. Their function is to memorize the characteristics of the antigen that activated their parent B cell during initial infection such that if the memory B cell later encounters the same antigen, it triggers an accelerated and robust secondary immune response. A naive B cell is a B cell that has not been exposed to an antigen. Once exposed to an antigen, the naive B cell either becomes a memory B cell or a plasma cell that secretes antibodies specific to the antigen that was originally bound.

Time frame:
Baseline, Week 1 Day 2, Week 2, Week 3 Day 15, Weeks 4, 8, 12, 16, 20, 24, Week 24 plus 2 days, Weeks 25, 28, 36, 40, 44 and 48
Reported as:
Mean · percentage of cells
Change From Baseline in B Cells (CD19+), Memory (CD19+CD27+) and Naïve (CD19+CD27-[Negative]) B Cells
percentage of cellsCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
B Cells (CD19+): Baseline7.40 ± 4.1087.89 ± 3.8997.24 ± 4.5868.11 ± 2.6965.71 ± 2.3686.78 ± 2.097
B Cells (CD19+): Change from Baseline to Week 1 Day 2-6.55 ± 3.920-8.29 ± 3.850-6.54 ± 4.715-7.95 ± 2.719-5.66 ± 2.347-6.70 ± 2.123
B Cells (CD19+): Change from Baseline to Week 2-7.52 ± 3.175-7.80 ± 3.878-7.13 ± 4.617-6.95 ± 1.806-5.68 ± 2.362-6.73 ± 2.090
B Cells (CD19+): Change from Baseline to Week 3 Day 15-7.27 ± 4.053-7.80 ± 3.830-7.17 ± 4.592-8.03 ± 2.714-5.69 ± 2.369-6.72 ± 2.080
B Cells (CD19+): Change from Baseline to Week 4-7.28 ± 4.127-7.79 ± 3.859-6.82 ± 4.889-8.03 ± 2.717-6.03 ± 2.322-6.71 ± 2.102
B Cells (CD19+): Change from Baseline to Week 8-7.29 ± 4.102-7.79 ± 3.886-7.15 ± 4.625-8.03 ± 3.032-5.69 ± 2.358-6.70 ± 2.065
B Cells (CD19+): Change from Baseline to Week 12-7.47 ± 4.592-7.77 ± 3.823-7.17 ± 4.617-8.45 ± 2.644-5.35 ± 2.317-7.14 ± 1.820
B Cells (CD19+): Change from Baseline to Week 16-7.01 ± 4.352-7.53 ± 4.110-7.75 ± 4.628-7.83 ± 2.667-5.68 ± 2.375-6.89 ± 2.178
B Cells (CD19+): Change from Baseline to Week 20-7.23 ± 4.116-8.07 ± 4.449-7.18 ± 4.637-7.58 ± 2.740-5.70 ± 2.534-6.65 ± 2.200
B Cells (CD19+): Change from Baseline to Week 24-7.21 ± 4.068-7.53 ± 3.399-7.76 ± 4.478-7.39 ± 2.940-5.65 ± 2.377-5.62 ± 1.992
B Cells (CD19+): Change from Baseline to Week 24 Plus 2 Days-7.31 ± 4.108-6.45 ± 2.919-7.98 ± 4.430-7.88 ± 2.895-6.29 ± 2.403-7.47 ± 1.983
B Cells (CD19+): Change from Baseline to Week 25-6.45 ± 3.698-8.20 ± 4.007-7.88 ± 4.512-8.06 ± 2.694-5.57 ± 2.544-7.47 ± 2.008
B Cells (CD19+): Change from Baseline to Week 28-7.31 ± 4.106-6.81 ± 2.844-7.18 ± 4.597-8.00 ± 2.699-5.65 ± 2.360-6.64 ± 2.258
B Cells (CD19+): Change from Baseline to Week 36-7.32 ± 4.082-6.79 ± 2.820-7.18 ± 4.601-8.48 ± 2.905-5.69 ± 2.530-6.64 ± 2.255
B Cells (CD19+): Change from Baseline to Week 40-5.40 ± 3.828-6.74 ± 2.838-7.15 ± 4.567-7.77 ± 3.132-5.65 ± 2.343-6.56 ± 2.299
B Cells (CD19+): Change from Baseline to Week 44-7.32 ± 4.092-6.74 ± 2.801-7.05 ± 4.546-8.06 ± 2.860-5.65 ± 2.341-6.59 ± 2.296
B Cells (CD19+): Change from Baseline to Week 48-7.25 ± 4.086-6.71 ± 2.854-6.87 ± 4.542-7.73 ± 2.621-5.67 ± 2.342-7.39 ± 2.174
Memory (CD19+CD27+): Baseline0.38 ± 0.3370.92 ± 0.7220.90 ± 1.0100.68 ± 0.4570.88 ± 0.9970.60 ± 0.367
Memory (CD19+CD27+): Change from Baseline to Week 1 Day 2-0.28 ± 0.279-0.92 ± 0.728-0.90 ± 1.098-0.59 ± 0.480-0.85 ± 1.001-0.54 ± 0.357
Memory (CD19+CD27+): Change from Baseline to Week 2-0.32 ± 0.354-0.86 ± 0.713-0.83 ± 1.032-0.46 ± 0.411-0.86 ± 1.003-0.57 ± 0.357
Memory (CD19+CD27+): Change from Baseline to Week 3 Day 15-0.31 ± 0.285-0.86 ± 0.694-0.86 ± 1.007-0.63 ± 0.468-0.87 ± 1.001-0.57 ± 0.382
Memory (CD19+CD27+): Change from Baseline to Week 4-0.31 ± 0.347-0.85 ± 0.690-0.64 ± 0.910-0.64 ± 0.465-0.91 ± 1.072-0.55 ± 0.396
Memory (CD19+CD27+): Change from Baseline to Week 8-0.32 ± 0.331-0.86 ± 0.736-0.85 ± 1.030-0.64 ± 0.552-0.87 ± 0.994-0.55 ± 0.381
Memory (CD19+CD27+): Change from Baseline to Week 12-0.36 ± 0.364-0.83 ± 0.668-0.87 ± 1.019-0.69 ± 0.494-0.92 ± 1.068-0.60 ± 0.381
Memory (CD19+CD27+): Change from Baseline to Week 16-0.30 ± 0.355-0.92 ± 0.769-0.93 ± 1.068-0.65 ± 0.456-0.87 ± 1.004-0.56 ± 0.427
Memory (CD19+CD27+): Change from Baseline to Week 20-0.27 ± 0.335-0.86 ± 0.849-1.07 ± 1.101-0.64 ± 0.431-0.88 ± 1.064-0.52 ± 0.421
Memory (CD19+CD27+): Change from Baseline to Week 24-0.30 ± 0.340-0.84 ± 0.656-0.96 ± 1.038-0.69 ± 0.442-0.86 ± 1.007-0.59 ± 0.444
Memory (CD19+CD27+): Change from Baseline to Week 24 Plus 2 Days-0.34 ± 0.330-0.74 ± 0.434-0.76 ± 0.875-0.59 ± 0.469-0.91 ± 1.168-0.65 ± 0.469
Memory (CD19+CD27+): Change from Baseline to Week 25-0.28 ± 0.371-0.97 ± 0.738-0.98 ± 1.057-0.65 ± 0.465-0.95 ± 1.033-0.61 ± 0.404
Memory (CD19+CD27+): Change from Baseline to Week 28-0.34 ± 0.336-0.68 ± 0.442-0.87 ± 1.021-0.62 ± 0.508-0.85 ± 0.971-0.60 ± 0.368
Memory (CD19+CD27+): Change from Baseline to Week 36-0.34 ± 0.322-0.68 ± 0.436-0.87 ± 1.020-0.75 ± 0.495-0.88 ± 1.069-0.59 ± 0.400
Memory (CD19+CD27+): Change from Baseline to Week 40-0.20 ± 0.086-0.68 ± 0.441-0.86 ± 1.012-0.62 ± 0.450-0.85 ± 0.975-0.57 ± 0.424
Memory (CD19+CD27+): Change from Baseline to Week 44-0.34 ± 0.341-0.66 ± 0.429-0.85 ± 0.997-0.69 ± 0.462-0.85 ± 1.008-0.62 ± 0.444
Memory (CD19+CD27+): Change from Baseline to Week 48-0.32 ± 0.344-0.65 ± 0.463-0.83 ± 0.983-0.62 ± 0.433-0.86 ± 1.007-0.71 ± 0.414
Naïve (CD19+CD27-): Baseline6.92 ± 3.8377.30 ± 3.1886.26 ± 4.0437.00 ± 2.1354.73 ± 2.2066.11 ± 2.096
Naïve (CD19+CD27-): Change from Baseline to Week 1 Day 2-6.18 ± 3.665-7.29 ± 3.427-5.56 ± 3.954-6.93 ± 2.132-4.72 ± 2.203-6.09 ± 2.100
Naïve (CD19+CD27-): Change from Baseline to Week 2-7.09 ± 2.899-7.27 ± 3.177-6.23 ± 4.058-6.18 ± 1.723-4.73 ± 2.205-6.10 ± 2.089
Naïve (CD19+CD27-): Change from Baseline to Week 3 Day 15-6.86 ± 3.805-7.27 ± 3.161-6.23 ± 4.043-6.97 ± 2.137-4.73 ± 2.205-6.09 ± 2.081
Naïve (CD19+CD27-): Change from Baseline to Week 4-6.87 ± 3.836-7.26 ± 3.173-6.13 ± 4.342-6.96 ± 2.134-5.02 ± 2.211-6.09 ± 2.092
Naïve (CD19+CD27-): Change from Baseline to Week 8-6.88 ± 3.831-7.26 ± 3.173-6.22 ± 4.057-6.99 ± 2.322-4.73 ± 2.203-6.08 ± 2.093
Naïve (CD19+CD27-): Change from Baseline to Week 12-7.00 ± 4.287-7.26 ± 3.175-6.23 ± 4.061-7.29 ± 2.060-4.36 ± 2.100-6.47 ± 1.907
Naïve (CD19+CD27-): Change from Baseline to Week 16-6.61 ± 4.067-7.00 ± 3.341-6.74 ± 4.085-6.76 ± 2.098-4.73 ± 2.209-6.27 ± 2.184
Naïve (CD19+CD27-): Change from Baseline to Week 20-6.87 ± 3.828-7.67 ± 3.234-6.02 ± 3.994-6.52 ± 2.214-4.73 ± 2.377-6.06 ± 2.139
Naïve (CD19+CD27-): Change from Baseline to Week 24-6.81 ± 3.788-7.02 ± 2.809-6.71 ± 4.024-6.26 ± 2.275-4.71 ± 2.207-4.96 ± 1.658
Naïve (CD19+CD27-): Change from Baseline to Week 24 Plus 2 Days-6.87 ± 3.842-6.18 ± 2.666-7.15 ± 4.231-6.81 ± 2.272-5.28 ± 2.286-6.74 ± 2.156
Naïve (CD19+CD27-): Change from Baseline to Week 25-6.13 ± 3.473-7.61 ± 3.257-6.81 ± 4.012-6.98 ± 2.132-4.52 ± 2.305-6.74 ± 2.148
Naïve (CD19+CD27-): Change from Baseline to Week 28-6.87 ± 3.837-6.53 ± 2.612-6.24 ± 4.047-6.95 ± 2.139-4.71 ± 2.208-5.97 ± 2.235
Naïve (CD19+CD27-): Change from Baseline to Week 36-6.89 ± 3.830-6.52 ± 2.594-6.23 ± 4.051-7.22 ± 2.249-4.72 ± 2.374-5.97 ± 2.233
Naïve (CD19+CD27-): Change from Baseline to Week 40-5.18 ± 3.740-6.46 ± 2.565-6.21 ± 4.042-6.63 ± 2.419-4.72 ± 2.204-5.92 ± 2.266
Naïve (CD19+CD27-): Change from Baseline to Week 44-6.89 ± 3.831-6.48 ± 2.573-6.13 ± 4.050-6.98 ± 2.283-4.72 ± 2.204-5.94 ± 2.248
Naïve (CD19+CD27-): Change from Baseline to Week 48-6.83 ± 3.809-6.46 ± 2.580-5.96 ± 4.091-6.69 ± 2.060-4.73 ± 2.205-6.60 ± 2.292
SecondaryChange From Baseline in Sustained B Cell

Sustained B cell reduction is defined as B-cell reductions achieved on pre-dose at Week 24 and Week 48.

Time frame:
Baseline to pre-dose at Week 24 and Week 48
Reported as:
Mean · percentage of cells
Change From Baseline in Sustained B Cell
percentage of cellsCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Baseline7.40 ± 4.1087.89 ± 3.8997.24 ± 4.5868.11 ± 2.6965.71 ± 2.3686.78 ± 2.097
Change at Pre-dose at Week 24-7.21 ± 4.068-7.53 ± 3.399-7.76 ± 4.478-7.39 ± 2.940-5.65 ± 2.377-5.62 ± 1.992
Change at Pre-dose at Week 48-7.25 ± 4.086-6.71 ± 2.854-6.87 ± 4.542-7.73 ± 2.621-5.67 ± 2.342-7.39 ± 2.174
SecondaryAdditional Immune Profiling-CD4+ (Cluster of Differentiation 4 Positive)

A blood sample was collected and was sent to the laboratory for analysis of CD4+.

Time frame:
Baseline, Week 1 Day 2, Week 2, Week 3 Day 15, Weeks 4, 8, 12, 16, 20, 24, Week 24 Plus 2 Days, Weeks 25, 28, 36, 40, 44 and 48
Reported as:
Mean · cells per cubic millimeter (cells/mm^3)
Additional Immune Profiling-CD4+ (Cluster of Differentiation 4 Positive)
cells per cubic millimeter (cells/mm^3)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Baseline28.73 ± 12.19535.39 ± 4.62824.34 ± 12.87725.75 ± 6.87422.70 ± 9.48822.27 ± 10.588
Week 1 Day 222.71 ± 15.82927.52 ± 11.38819.51 ± 9.12916.98 ± 11.62416.49 ± 13.98514.15 ± 5.911
Week 234.01 ± 7.19039.83 ± 8.82933.31 ± 4.86236.51 ± 9.28928.50 ± 8.17325.69 ± 8.761
Week 3 Day 1523.74 ± 11.39926.51 ± 10.65022.60 ± 7.76627.68 ± 13.65619.88 ± 13.90224.57 ± 11.080
Week 426.19 ± 11.92235.31 ± 11.53031.47 ± 8.65830.97 ± 12.84024.62 ± 8.08727.59 ± 11.016
Week 829.74 ± 15.73531.46 ± 8.38729.64 ± 8.20430.95 ± 14.62527.73 ± 9.16224.59 ± 4.511
Week 1224.20 ± 8.15232.26 ± 7.11830.98 ± 11.47627.71 ± 9.20928.03 ± 12.04524.09 ± 8.087
Week 1624.03 ± 10.04031.55 ± 7.55719.19 ± 10.46631.27 ± 12.13127.37 ± 14.73317.85 ± 4.155
Week 2022.94 ± 9.49226.87 ± 11.62934.25 ± 8.92833.56 ± 8.53727.17 ± 7.90824.51 ± 13.149
Week 2429.24 ± 8.67829.36 ± 8.85631.33 ± 13.40629.12 ± 7.00626.71 ± 9.60317.41 ± 7.523
Week 24 Plus 2 Days26.25 ± 8.12027.54 ± 5.26922.82 ± 17.38536.47 ± 12.54823.59 ± 6.91221.22 ± 8.474
Week 2530.70 ± 8.59427.31 ± 13.09135.42 ± 8.85428.46 ± 9.80127.96 ± 6.02417.57 ± 10.438
Week 2820.03 ± 11.87031.70 ± 13.65429.71 ± 13.05123.57 ± 10.56523.09 ± 8.85521.64 ± 14.610
Week 3626.79 ± 14.20928.06 ± 9.43637.56 ± 8.66422.86 ± 8.41314.73 ± 5.91628.20 ± 15.386
Week 4025.31 ± 10.66430.91 ± 10.60128.45 ± 11.49728.10 ± 9.46418.17 ± 11.19226.68 ± 17.744
Week 4424.77 ± 6.46929.84 ± 9.01329.83 ± 10.77417.17 ± 9.92026.22 ± 14.34028.24 ± 12.190
Week 4826.72 ± 6.91432.92 ± 6.69721.90 ± 7.77922.60 ± 8.93530.85 ± 13.01627.03 ± 7.844
SecondaryAdditional Immune Profiling-CD8+ (Cluster of Differentiation 8 Positive)

A blood sample was collected and was sent to the laboratory for analysis of CD8+.

Time frame:
Baseline, Week 1 Day 2, Week 2, Week 3 Day 15, Weeks 4, 8, 12, 16, 20, 24, Week 24 Plus 2 Days, Weeks 25, 28, 36, 40, 44 and 48
Reported as:
Mean · cells/mm^3
Additional Immune Profiling-CD8+ (Cluster of Differentiation 8 Positive)
cells/mm^3Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Baseline16.80 ± 5.32417.50 ± 5.2229.97 ± 4.87712.25 ± 2.3748.72 ± 3.59012.83 ± 6.576
Week 1 Day 210.04 ± 6.69812.06 ± 6.5246.87 ± 2.7465.93 ± 2.7485.14 ± 2.7797.61 ± 5.157
Week 217.03 ± 3.65416.96 ± 7.86913.22 ± 3.14114.68 ± 2.37711.14 ± 4.76714.22 ± 9.157
Week 3 Day 1512.14 ± 6.64611.88 ± 6.5809.21 ± 4.78012.10 ± 6.0337.22 ± 4.10312.50 ± 6.536
Week 413.89 ± 5.71514.89 ± 7.81511.78 ± 3.26313.70 ± 5.2969.89 ± 2.12013.49 ± 5.214
Week 815.92 ± 8.48913.91 ± 5.07410.97 ± 3.01212.80 ± 7.5679.63 ± 3.05612.62 ± 5.613
Week 1215.21 ± 8.12217.21 ± 6.80711.83 ± 5.39711.06 ± 3.7738.93 ± 4.18514.87 ± 9.608
Week 1616.25 ± 6.95113.87 ± 7.4316.76 ± 3.61312.51 ± 3.82710.63 ± 6.20310.86 ± 5.193
Week 2015.04 ± 7.19710.35 ± 5.99810.04 ± 3.13213.71 ± 3.45010.29 ± 5.15012.98 ± 7.476
Week 2415.83 ± 4.04713.77 ± 5.50911.59 ± 5.41712.22 ± 5.37212.05 ± 6.8599.45 ± 6.093
Week 24 Plus 2 Days14.70 ± 3.65513.28 ± 6.7277.05 ± 4.65615.52 ± 5.8398.90 ± 1.5089.41 ± 3.298
Week 2515.38 ± 6.71712.48 ± 4.47512.07 ± 4.77311.60 ± 4.1729.78 ± 2.3958.94 ± 6.287
Week 2811.15 ± 4.59912.84 ± 5.52210.63 ± 6.61711.02 ± 3.0309.32 ± 2.1219.71 ± 3.160
Week 3612.92 ± 7.72111.95 ± 5.49312.46 ± 2.84010.11 ± 4.5276.92 ± 3.15811.59 ± 2.584
Week 4014.63 ± 3.68712.77 ± 7.6549.82 ± 3.92611.59 ± 4.4857.93 ± 2.20710.30 ± 4.027
Week 4414.41 ± 6.08511.46 ± 2.4519.91 ± 3.9378.67 ± 5.0739.59 ± 3.92211.87 ± 3.352
Week 4813.28 ± 6.67312.79 ± 5.2327.42 ± 2.2769.86 ± 5.26011.68 ± 5.75713.50 ± 3.412
SecondaryAdditional Immune Profiling-Interleukin 10 (IL10)

A blood sample was collected and was sent to the laboratory for analysis of IL-10. IL-10 is an anti-inflammatory cytokine that maintains the balance of the immune response, allowing the clearance of infection while minimizing damage to the host.

Time frame:
Baseline, Weeks 2, 4, 12, 20, 24, 25, 36, 44 and 48
Reported as:
Mean · picogram per milliliter (pg/ml)
Additional Immune Profiling-Interleukin 10 (IL10)
picogram per milliliter (pg/ml)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Baseline0.25 ± 0.1750.37 ± 0.3430.41 ± 0.4590.40 ± 0.2470.13 ± 0.1290.09 ± 0.120
Week 20.39 ± 0.2580.39 ± 0.3500.27 ± 0.1840.42 ± 0.0700.16 ± 0.1430.07 ± 0.120
Week 40.53 ± 0.2940.42 ± 0.2900.40 ± 0.2860.34 ± 0.1350.62 ± 1.0590.25 ± 0.358
Week 120.57 ± 0.5990.89 ± 1.2230.70 ± 0.7830.26 ± 0.4220.04 ± 0.0281.19 ± 1.147
Week 200.24 ± 0.1600.65 ± 0.6310.24 ± 0.1410.13 ± 0.2130.57 ± 0.4670.64 ± 0.593
Week 240.43 ± 0.4540.45 ± 0.3630.49 ± 0.6350.29 ± 0.3252.14 ± 3.3290.91 ± 0.778
Week 250.32 ± 0.1630.40 ± 0.2370.18 ± 0.2920.24 ± 0.2371.31 ± 1.1681.36 ± 0.922
Week 360.21 ± 0.1240.36 ± 0.5430.08 ± 0.0680.79 ± 0.7690.95 ± 0.5350.82 ± 0.303
Week 440.15 ± 0.1640.35 ± 0.7152.77 ± 3.1011.25 ± 1.2680.65 ± 0.4522.11 ± 1.533
Week 480.07 ± 0.0630.44 ± 0.5511.87 ± 1.4653.13 ± 5.5520.68 ± 0.7731.23 ± 0.568
SecondaryAdditional Immune Profiling-Natural Killer (NK) Cells

A blood sample was collected and was sent to the laboratory for analysis of NK cells. Percentage of NK cells per ml of blood. NK cells are lymphocytes with the ability to kill tumor cells without deliberate immunization or activation.

Time frame:
Baseline, Week 1 Day 2, Week 2, Week 3 Day 15, Weeks 4, 8, 12, 16, 20, 24, Week 24 Plus 2 Days, Weeks 25, 28, 36, 40, 44 and 48
Reported as:
Mean · percentage of cells/mL
Additional Immune Profiling-Natural Killer (NK) Cells
percentage of cells/mLCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6
Baseline6.53 ± 2.8297.22 ± 4.4695.06 ± 2.6187.68 ± 3.7245.04 ± 2.7194.67 ± 1.946
Week 1 Day 21.98 ± 1.5972.01 ± 2.4652.11 ± 1.3861.38 ± 0.6801.10 ± 0.3721.08 ± 0.980
Week 27.34 ± 6.8626.03 ± 5.0016.27 ± 1.2307.93 ± 2.8616.17 ± 3.5884.09 ± 1.920
Week 3 Day 154.99 ± 1.6476.62 ± 5.8405.63 ± 2.7925.93 ± 4.6793.50 ± 1.7174.40 ± 2.570
Week 46.45 ± 3.1897.88 ± 8.1317.49 ± 2.2425.72 ± 2.4586.12 ± 5.4404.80 ± 3.352
Week 86.22 ± 4.7617.53 ± 4.3476.79 ± 4.1724.80 ± 2.4634.81 ± 2.5736.21 ± 4.520
Week 125.47 ± 2.1146.33 ± 3.0536.71 ± 2.3285.25 ± 2.4943.46 ± 1.4695.71 ± 2.446
Week 1610.49 ± 5.7475.28 ± 2.5485.91 ± 3.1365.34 ± 3.0575.58 ± 4.5787.34 ± 6.747
Week 2010.17 ± 7.7914.46 ± 2.6386.81 ± 4.9945.73 ± 2.1055.79 ± 3.1448.03 ± 7.391
Week 246.70 ± 4.8836.51 ± 3.7815.84 ± 2.8904.55 ± 2.2438.51 ± 5.4849.81 ± 3.968
Week 24 Plus 2 Days8.31 ± 9.5134.45 ± 4.0723.75 ± 2.4223.38 ± 1.6845.83 ± 3.7114.97 ± 1.110
Week 2511.45 ± 6.5996.56 ± 4.8495.91 ± 3.1333.71 ± 2.1996.51 ± 3.5418.34 ± 5.602
Week 288.06 ± 7.6745.47 ± 4.3265.69 ± 3.2184.73 ± 3.3348.29 ± 5.6646.95 ± 2.970
Week 366.63 ± 3.6486.36 ± 7.2565.72 ± 1.2757.88 ± 5.5158.22 ± 5.7729.58 ± 7.535
Week 409.17 ± 4.5274.67 ± 3.1095.20 ± 2.9046.18 ± 2.9016.64 ± 3.0706.90 ± 3.244
Week 447.20 ± 7.7644.40 ± 3.4815.00 ± 1.7338.97 ± 6.0086.59 ± 4.7777.14 ± 3.195
Week 483.84 ± 2.0815.23 ± 4.9436.72 ± 1.9606.94 ± 3.6017.05 ± 4.4466.10 ± 1.930
SecondaryPharmacokinetic Parameter: Plasma Concentration of Ublituximab

Plasma concentration is defined as the measured concentration of ublituximab.

Time frame:
Day 1 (pre-dose); Week 2; Day 15 (pre-dose); Weeks 4, 24 (pre-dose) and 25

No measurements were reported for this outcome.

Adverse events

Collected over From the first dose of study medication through the end of the study (Up to 48 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/8 (0%)0/8 (0%)8/8 (100%)
Cohort 20/8 (0%)1/8 (12.5%)7/8 (87.5%)
Cohort 30/8 (0%)2/8 (25%)8/8 (100%)
Cohort 40/8 (0%)0/8 (0%)8/8 (100%)
Cohort 50/8 (0%)0/8 (0%)8/8 (100%)
Cohort 60/8 (0%)2/8 (25%)8/8 (100%)
Placebo0/13 (0%)0/13 (0%)12/13 (92.3%)
Most frequent serious events
Most frequent serious events
EventCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Placebo
SeizureNervous system disorders0/80/81/80/80/80/80/13
DiverticulumGastrointestinal disorders0/80/81/80/80/80/80/13
CholelithiasisHepatobiliary disorders0/80/81/80/80/80/80/13
AppendicitisInfections and infestations0/80/80/80/80/81/80/13
PregnancyPregnancy, puerperium and perinatal conditions0/81/80/80/80/80/80/13
Pregnancy of partnerSocial circumstances0/80/80/80/80/81/80/13
Most frequent other events
Showing 10 of 146
Most frequent other events
EventCohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Placebo
NauseaGastrointestinal disorders0/83/81/80/80/85/82/13
FatigueGeneral disorders0/83/82/84/82/83/85/13
HeadacheNervous system disorders2/83/81/82/82/82/82/13
HypoaesthesiaNervous system disorders2/82/80/80/80/83/81/13
DizzinessNervous system disorders0/83/80/80/81/83/83/13
Upper respiratory tract infectionInfections and infestations2/80/81/81/83/80/81/13
SinusitisInfections and infestations1/80/81/83/80/80/82/13
NasopharyngitisInfections and infestations0/80/81/83/80/81/80/13
DysphagiaGastrointestinal disorders0/81/80/80/83/80/82/13
Back painMusculoskeletal and connective tissue disorders3/81/80/81/80/81/80/13

Baseline characteristics

Intent-to-Treat (ITT) population included all participants who received at least one dose of ublituximab.

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Total
Mean42.4 ± 12.0934.3 ± 9.1344.9 ± 9.0635.1 ± 9.2243.5 ± 6.3936.5 ± 8.3339.4 ± 9.70
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Total
Female56558332
Male32330516
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Total
Hispanic or Latino0212139
Not Hispanic or Latino86767539
Unknown or Not Reported0000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Cohort 6Total
Race — Black or African American2022017
Race — White67668639
Race — Other0100012
08

Study locations

12 sites
  • TG Therapeutics Investigational Trial Site
    Phoenix, Arizona 85018, United States
  • TG Therapeutics Investigational Trial Site
    Pasadena, California 91105, United States
  • TG Therapeutics Investigational Trial Site
    Torrance, California 90502, United States
  • TG Therapeutics Investigational Trial Site
    Aurora, Colorado 80045, United States
  • TG Therapeutics Investigational Trial Site
    Fort Collins, Colorado 80528, United States
  • TG Therapeutics Investigational Trial Site
    Lexington, Kentucky 40509, United States
  • TG Therapeutics Investigational Trial Site
    Teaneck, New Jersey 07666, United States
  • TG Therapeutics Investigational Trial Site
    Akron, Ohio 44320, United States
  • TG Therapeutics Investigational Trial Site
    Columbus, Ohio 43201, United States
  • TG Therapeutics Investigational Trial Site
    Knoxville, Tennessee 37922, United States
  • TG Therapeutics Investigational Trial Site
    Round Rock, Texas 78681, United States
  • TG Therapeutics Investigational Trial Site
    San Antonio, Texas 78258, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Data will be shared after study completion via publication

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Sep 2017, 16 months.

Results were first posted in Jul 2021, 3 years 9 months after primary completion.

Of 43 industry-sponsored phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 16 months is below that.

Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2016
First posted
Apr 14, 2016
StartActual
May 27, 2016
Primary completionActual
Sep 27, 2017
CompletionActual
Aug 13, 2018
Results first posted
Jul 15, 2021
Last update
Jul 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02738775
Responsible party
Sponsor
First posted
Apr 14, 2016
Start date
May 27, 2016
Primary completion
Sep 27, 2017
Completion
Aug 13, 2018
Results posted
Jul 15, 2021
Last update
Jul 15, 2021

Study contacts

Edward Fox, MD, PhD
study chair · Central Texas Neurology

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ublituximab

Start the discussion